Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated

Treatment Strategies: Turning Off the Faucet

At a Glance

Amyloidosis treatment aims to stop abnormal protein production based on your subtype. AL is treated with plasma cell therapies like Dara-CyBorD, ATTR uses genetic silencers or protein stabilizers, and AA targets underlying inflammation.

Treating amyloidosis is often described using the analogy of a leaking faucet and an overflowing sink. The amyloid deposits in your organs are the water in the sink. The protein production in your body is the leaking faucet. Current medical strategies focus on “turning off the faucet” to prevent more damage, while supportive care helps manage the “overflow” in your organs [1][2].

AL Amyloidosis: Stopping the Plasma Cells

In AL amyloidosis, the “faucet” is a group of abnormal plasma cells in your bone marrow. Treatment aims to eliminate these cells so they stop producing the toxic light chain proteins [3].

  • Standard of Care (2023-2024): The most common initial treatment is a combination called Dara-CyBorD [1].
    • Daratumumab: A monoclonal antibody that targets and kills the abnormal plasma cells [4].
    • CyBorD: A mix of cyclophosphamide, bortezomib (Velcade), and dexamethasone [5].
  • Autologous Stem Cell Transplant (ASCT): This is a highly effective, intensive treatment where your own healthy stem cells are collected, high-dose chemotherapy is given to reset the bone marrow, and the stem cells are returned [6].
    • Eligibility: Not everyone is a candidate. Doctors look for “fit” patients, typically under age 70, with strong heart function (Troponin T < 0.06 ng/mL) and healthy kidneys (creatinine ≤ 1.7 mg/dL) [7][8].

ATTR Amyloidosis: Stabilizers and Silencers

For ATTR amyloidosis, the protein is made in the liver. Treatment strategies are divided into two main categories:

  1. TTR Stabilizers (e.g., Tafamidis): Think of these as “glue.” They bind to the TTR protein and keep it in its correct shape so it cannot break apart and form amyloid clumps [9]. This is primarily used for patients with heart involvement (ATTR-CM) [10].
  2. TTR Silencers (e.g., Patisiran, Vutrisiran, Inotersen): These drugs “turn off the faucet” at the genetic level. They tell the liver to stop producing the TTR protein almost entirely [11][12]. These are often used for patients with nerve damage (ATTRv-PN) or combined heart and nerve issues [13].

AA Amyloidosis: Treating the Root Cause

AA amyloidosis is a “secondary” condition caused by long-term inflammation. The “faucet” in this case is an underlying disease like Rheumatoid Arthritis, Crohn’s Disease, or a chronic infection [2][14].

  • Targeted Biologicals: If the underlying disease is not controlled by standard medicine, doctors may use powerful drugs to block inflammation:
    • IL-1 Inhibitors (Anakinra): Often used if the cause is an autoinflammatory syndrome [15].
    • IL-6 Inhibitors (Tocilizumab): Used to aggressively lower inflammation and potentially allow existing amyloid deposits to regress [16][17].

Summary of Treatment Logic

Strategy How it Works Example Medications
“Turn off the Faucet” Stops the production of the bad protein. Daratumumab (AL), Vutrisiran (ATTR), Tocilizumab (AA)
“Stabilize the Protein” Prevents the protein from misfolding. Tafamidis (ATTR)
“Clean the Sink” Managing organ symptoms (supportive care). Diuretics for heart, physical therapy for nerves

Your medical team will choose the strategy that best matches your subtype and how much your organs are currently affected [18][19].

Common questions in this guide

What is the primary goal of amyloidosis treatment?
The main goal is to stop the body from producing abnormal proteins, a strategy often described as "turning off the faucet." Alongside this, doctors use supportive care to manage symptoms and help organs that have already been damaged.
How is AL amyloidosis treated?
AL amyloidosis is typically treated by targeting abnormal plasma cells in the bone marrow. The standard approach involves medication combinations like Dara-CyBorD, and eligible patients may also undergo an autologous stem cell transplant.
What is the difference between stabilizers and silencers?
These are medications used for ATTR amyloidosis. Stabilizers act like glue to keep the protein from breaking apart and forming clumps. Silencers work at the genetic level to tell the liver to stop producing the problem protein almost entirely.
Can other diseases cause amyloidosis?
Yes, AA amyloidosis is caused by chronic inflammation from underlying conditions such as rheumatoid arthritis or Crohn's disease. Treatment focuses on using powerful anti-inflammatory drugs to control that root cause.
How do doctors decide if I can get a stem cell transplant?
Eligibility for a stem cell transplant depends on your overall fitness, age, and organ function. Doctors carefully evaluate heart markers like troponin and kidney function tests to ensure the procedure is safe for you.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific subtype, what is our primary goal of treatment right now: turning off the protein production or stabilizing what is already there?
  2. 2.For AL: Am I currently a candidate for a stem cell transplant, and if not, what are the specific 'markers' (like troponin or kidney function) that would need to improve for me to become eligible?
  3. 3.For ATTR: Should I be on a 'stabilizer' like tafamidis, a 'silencer' like vutrisiran, or a combination of both?
  4. 4.For AA: Which specific inflammatory marker (like CRP or SAA) are we tracking to see if the underlying disease is under control?
  5. 5.What are the most common side effects of the medications you are recommending, and how will we manage them?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management.

    Tan M, Chen Y, Ooi M, et al.

    Annals of the Academy of Medicine, Singapore 2023; (52(11)):601-624 doi:10.47102/annals-acadmedsg.2023101.

    PMID: 38920149
  2. 2

    Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage.

    Scarpioni R, Ricardi M, Albertazzi V

    World journal of nephrology 2016; (5(1)):66-75 doi:10.5527/wjn.v5.i1.66.

    PMID: 26788465
  3. 3

    Primary systemic amyloidosis: A brief overview.

    Hughes MS, Lentzsch S

    Presse medicale (Paris, France : 1983) 2025; (54(1)):104267 doi:10.1016/j.lpm.2024.104267.

    PMID: 39672504
  4. 4

    Treatment Approach for Advanced Systemic Light Chain Amyloidosis: A Case Report.

    Hachem MAM, Nasreddine GM, Farhat S, et al.

    Cureus 2024; (16(8)):e65960 doi:10.7759/cureus.65960.

    PMID: 39221331
  5. 5

    A pharmacist's review of the treatment of systemic light chain amyloidosis.

    Hughes DM, Staron A, Sanchorawala V

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021; (27(1)):187-198 doi:10.1177/1078155220963534.

    PMID: 33028132
  6. 6

    Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.

    Gustine JN, Staron A, Szalat RE, et al.

    American journal of hematology 2022; (97(9)):1189-1199 doi:10.1002/ajh.26641.

    PMID: 35731907
  7. 7

    Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.

    Gertz MA

    American journal of hematology 2020; (95(7)):848-860 doi:10.1002/ajh.25819.

    PMID: 32267020
  8. 8

    Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis.

    Gutiérrez-García G, Cibeira MT, Rovira M, et al.

    Bone marrow transplantation 2019; (54(8)):1295-1303 doi:10.1038/s41409-019-0447-y.

    PMID: 30664727
  9. 9

    Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.

    Lamb YN

    American journal of cardiovascular drugs : drugs, devices, and other interventions 2021; (21(1)):113-121 doi:10.1007/s40256-020-00461-7.

    PMID: 33469827
  10. 10

    Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.

    Park J, Egolum U, Parker S, et al.

    The Annals of pharmacotherapy 2020; (54(5)):470-477 doi:10.1177/1060028019888489.

    PMID: 31735059
  11. 11

    Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.

    Kristen AV, Ajroud-Driss S, Conceição I, et al.

    Neurodegenerative disease management 2019; (9(1)):5-23 doi:10.2217/nmt-2018-0033.

    PMID: 30480471
  12. 12

    Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.

    Fontana M, Berk JL, Gillmore JD, et al.

    The New England journal of medicine 2025; (392(1)):33-44 doi:10.1056/NEJMoa2409134.

    PMID: 39213194
  13. 13

    Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.

    Adams D, Koike H, Slama M, Coelho T

    Nature reviews. Neurology 2019; (15(7)):387-404 doi:10.1038/s41582-019-0210-4.

    PMID: 31209302
  14. 14

    The Clinical Features and Outcomes of Renal Amyloidosis in Tunisia.

    Ayed A, Salem MB, Letaief A, et al.

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2022; (33(3)):432-439 doi:10.4103/1319-2442.385967.

    PMID: 37843145
  15. 15

    AA amyloidosis of unknown aetiology: response to treatment with interleukin-1 inhibitors.

    İlgen U, Uçar İ, Kılıç G, Küçükşahin O

    Clinical kidney journal 2023; (16(6)):1038-1042 doi:10.1093/ckj/sfad005.

    PMID: 37261005
  16. 16

    Effectiveness of tocilizumab in Behcet's disease: A systematic literature review.

    Akiyama M, Kaneko Y, Takeuchi T

    Seminars in arthritis and rheumatism 2020; (50(4)):797-804 doi:10.1016/j.semarthrit.2020.05.017.

    PMID: 32544751
  17. 17

    Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.

    Lane T, Gillmore JD, Wechalekar AD, et al.

    Clinical and experimental rheumatology 2015; (33(6 Suppl 94)):S46-53.

    PMID: 26120866
  18. 18

    Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease.

    Kastritis E, Rousakis P, Kostopoulos IV, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(4)):259-266 doi:10.1080/13506129.2021.1971192.

    PMID: 34468250
  19. 19

    Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence.

    Ogieuhi IJ, Ugiomoh OM, Muzofa K, et al.

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2024; (76(1)):90 doi:10.1186/s43044-024-00517-y.

    PMID: 38985360

This page provides an educational overview of amyloidosis treatment strategies. Always consult your hematologist, cardiologist, or primary care team to determine the safest and most effective treatment plan for your specific subtype.

Get notified when new evidence is published on Amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.